Adaptive Hybrid Surgery Analysis

Make sure you choose the correct software version by selecting the Brainlab logo in the bottom corner of the corresponding software

OAR Analysis



Adaptive Hybrid Surgery Analysis analyzes the potential effect of each template plan on each OAR. To open the drop-down menu and see more details for an object, select the arrow to the left of the name.

For each plan, the actual result for the OAR is displayed with the given value (in brackets). For OARs, the given values set two objectives for the maximum dose an OAR should receive to be safe.

  • D₅₀: The limit of how much dose 50% of the object should receive

  • Max or Max Dose: The maximum dose limit for this object

The software additionally sets constraints for OARs. The constraint defines the maximum dose an OAR should receive to be tolerable (= 110% of the objective).

These visual indicators are used in the symbols.

  • Green: The objective is met.

  • Yellow: The objective is violated, but the constraint (maximum tolerable dose) is met.

  • Red: The objective and constraint (maximum tolerable dose) are violated.

Symbol Description


(All green)

The objective and constraint are met for both D₅₀ (50%) and Max Dose





(Outer green, inner red/yellow)

  • (Green) The objective and constraint are met for D₅₀

  • (Red) The objective and constraint are violated for Max Dose

  • (Yellow) The objective is violated, but the constraint is met forMax Dose





(Inner green, outer red/yellow)

  • (Green) The objective and constraint are met for Max Dose

  • (Red) The objective and constraint are violated for D₅₀

  • (Yellow) The objective is violated, but the constraint is met for D₅₀



(All red)

The objectives and constraints are violated for both D₅₀ and Max Dose



(All yellow)

The objectives are violated, but the constraints are met for both D₅₀ and Max Dose



(Grey)

It is not possible to calculate a viable dose plan for this data set. This may be because:

  • The OAR is not selected

  • D₅₀ and Max Dose are ignored

Article No. 60919-43EN

Date of publication: 2019-03-29